PriceTargets.com logo

McKesson - MCK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $533.50
  • Forecasted Upside: -1.19%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$539.94 As of 04/25/2024 01:00 AM ET
▲ +4.52 (0.84%)

This chart shows the closing price for MCK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New McKesson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MCK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MCK

Analyst Price Target is $533.50
▼ -1.19% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for McKesson in the last 3 months. The average price target is $533.50, with a high forecast of $620.00 and a low forecast of $475.00. The average price target represents a -1.19% upside from the last price of $539.94.

This chart shows the closing price for MCK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in McKesson. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$522.00 ➝ $548.00Low
4/10/2024ArgusBoost TargetBuy ➝ Buy$510.00 ➝ $570.00Low
3/6/2024UBS GroupBoost TargetBuy ➝ Buy$575.00 ➝ $620.00Low
2/26/2024Leerink PartnrsReiterated RatingOutperformLow
2/26/2024SVB LeerinkInitiated CoverageOutperform$600.00Low
2/9/2024MizuhoBoost TargetNeutral ➝ Neutral$450.00 ➝ $505.00Low
2/8/2024CitigroupBoost TargetBuy ➝ Buy$530.00 ➝ $575.00Low
1/29/2024UBS GroupBoost TargetBuy ➝ Buy$525.00 ➝ $559.00Low
1/3/2024BarclaysInitiated CoverageOverweight$537.00Low
12/14/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$502.00Low
12/11/2023TD CowenBoost TargetOutperform ➝ Outperform$508.00 ➝ $563.00Low
11/17/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$495.00 ➝ $514.00Low
11/3/2023MizuhoBoost TargetNeutral ➝ Neutral$427.00 ➝ $450.00Low
11/2/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$459.00 ➝ $480.00N/A
10/11/2023Evercore ISIBoost Target$485.00 ➝ $490.00Low
10/9/2023ArgusBoost TargetBuy ➝ Buy$450.00 ➝ $480.00Low
8/11/2023Credit Suisse GroupBoost TargetOutperform ➝ Outperform$450.00 ➝ $485.00Low
8/7/2023TD CowenBoost TargetOutperform ➝ Outperform$491.00 ➝ $495.00Low
8/3/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$426.00 ➝ $459.00Low
8/3/2023UBS GroupBoost TargetBuy ➝ Buy$470.00 ➝ $480.00Low
7/17/2023Bank of AmericaBoost Target$470.00 ➝ $485.00Low
7/11/2023MizuhoBoost Target$390.00 ➝ $427.00Low
6/29/2023ArgusBoost Target$430.00 ➝ $450.00Low
5/12/2023Credit Suisse GroupBoost Target$430.00 ➝ $450.00Low
5/9/202358.comReiterated RatingMaintainsLow
5/9/2023Bank of AmericaBoost Target$450.00 ➝ $470.00Low
5/9/2023Robert W. BairdBoost Target$450.00 ➝ $475.00Low
5/9/2023MizuhoBoost Target$376.00 ➝ $390.00Low
5/9/2023BarclaysBoost Target$415.00 ➝ $420.00Low
3/31/2023CitigroupInitiated CoverageBuy$420.00Low
2/2/2023Morgan StanleyBoost TargetOverweight$420.00 ➝ $426.00Low
2/2/2023Robert W. BairdBoost TargetOutperform$445.00 ➝ $450.00Low
1/31/2023UBS GroupLower TargetBuy$450.00 ➝ $440.00Low
1/11/2023Robert W. BairdBoost TargetOutperform$440.00 ➝ $445.00Low
1/6/2023Morgan StanleyBoost TargetOverweight$403.00 ➝ $420.00Low
11/14/2022MizuhoBoost TargetNeutral$345.00 ➝ $376.00Low
11/2/2022CowenBoost Target$384.00 ➝ $416.00Low
11/2/2022CowenBoost Target$384.00 ➝ $416.00Low
11/2/2022BarclaysBoost TargetEqual Weight$375.00 ➝ $415.00Low
11/2/2022Robert W. BairdBoost TargetOutperform$405.00 ➝ $440.00N/A
10/13/2022Robert W. BairdBoost Target$405.00Low
9/12/2022ArgusBoost TargetBuy$370.00 ➝ $430.00Low
8/22/2022Morgan StanleyBoost TargetOverweight$370.00 ➝ $403.00Low
8/9/2022CowenBoost Target$384.00Low
8/8/2022Deutsche Bank AktiengesellschaftBoost Target$378.00 ➝ $409.00Low
8/8/2022Credit Suisse GroupBoost TargetOutperform$377.00 ➝ $385.00Low
8/4/2022UBS GroupBoost TargetBuy$380.00 ➝ $400.00Low
8/4/2022Robert W. BairdBoost TargetOutperform$386.00 ➝ $400.00N/A
8/4/2022MizuhoBoost TargetNeutral$331.00 ➝ $345.00Low
7/6/2022ArgusDowngradeBuy ➝ HoldN/A
6/7/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$343.00 ➝ $378.00Low
5/19/2022UBS GroupBoost TargetHold$380.00Low
5/11/2022Credit Suisse GroupBoost Target$333.00 ➝ $377.00Low
5/10/2022Deutsche Bank AktiengesellschaftBoost Target$270.00 ➝ $343.00Low
5/9/2022MizuhoBoost Target$280.00 ➝ $331.00Low
5/6/2022Robert W. BairdBoost Target$352.00 ➝ $380.00High
4/18/2022CowenBoost Target$325.00 ➝ $361.00Low
4/18/2022CowenBoost TargetOutperform$325.00 ➝ $361.00Low
4/12/2022Morgan StanleyBoost TargetOverweight$292.00 ➝ $370.00Low
4/1/2022Credit Suisse GroupInitiated CoverageOutperform$333.00Low
2/8/2022UBS GroupBoost TargetBuy$245.00 ➝ $303.00Medium
2/7/2022MizuhoBoost TargetNeutral$250.00 ➝ $280.00High
2/4/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$262.00 ➝ $270.00Low
2/3/2022Robert W. BairdBoost Target$312.00 ➝ $340.00Low
1/7/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform$230.00 ➝ $333.00High
12/20/2021MizuhoBoost TargetNeutral$236.00 ➝ $250.00Medium
12/17/2021Morgan StanleyBoost TargetOverweight$252.00 ➝ $292.00Medium
12/10/2021Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$279.00 ➝ $262.00Medium
12/9/2021Bank of AmericaBoost TargetBuy ➝ Buy$250.00 ➝ $265.00Low
12/9/2021Robert W. BairdBoost TargetOutperform ➝ Outperform$280.00 ➝ $300.00High
12/9/2021MizuhoBoost TargetNeutral ➝ Neutral$229.00 ➝ $236.00High
12/9/2021BarclaysBoost TargetOverweight ➝ Overweight$270.00 ➝ $290.00High
12/6/2021Morgan StanleyBoost TargetOverweight$240.00 ➝ $250.00Low
12/6/2021CowenBoost TargetOutperform ➝ Outperform$268.00 ➝ $300.00High
11/8/2021ArgusBoost TargetBuy$230.00 ➝ $270.00Low
11/8/2021Credit Suisse GroupBoost TargetNeutral$224.00 ➝ $230.00Low
11/5/2021CowenBoost TargetOutperform$247.00 ➝ $268.00Low
11/3/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$261.00 ➝ $279.00High
11/3/2021MizuhoBoost TargetNeutral$210.00 ➝ $229.00High
11/2/2021Evercore ISIBoost TargetOutperform$225.00 ➝ $230.00High
11/2/2021Bank of AmericaBoost TargetBuy$237.00 ➝ $250.00High
11/2/2021Jefferies Financial GroupBoost TargetBuy$270.00 ➝ $280.00High
11/2/2021Robert W. BairdBoost TargetOutperform$254.00 ➝ $260.00High
11/2/2021BarclaysBoost TargetOverweight$255.00 ➝ $270.00High
10/29/2021Morgan StanleyBoost TargetOverweight$226.00 ➝ $240.00Medium
8/9/2021Credit Suisse GroupBoost TargetNeutral$222.00 ➝ $224.00Medium
8/5/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$237.00 ➝ $261.00High
5/12/2021MizuhoBoost TargetNeutral$190.00 ➝ $205.00Low
5/10/2021Credit Suisse GroupBoost TargetNeutral$192.00 ➝ $222.00Medium
5/7/2021The Goldman Sachs GroupBoost TargetBuy$231.00 ➝ $257.00High
5/7/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$231.00 ➝ $237.00High
3/30/2021ArgusUpgradeHold ➝ Buy$230.00Low
3/2/2021CowenBoost TargetPositive ➝ Outperform$210.00 ➝ $224.00Low
2/3/2021Morgan StanleyBoost TargetOverweight$219.00 ➝ $226.00Low
2/3/2021Credit Suisse GroupBoost TargetNeutral$178.00 ➝ $192.00Low
2/3/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$222.00 ➝ $231.00Low
2/3/2021MizuhoBoost TargetNeutral$178.00 ➝ $190.00Low
2/1/2021CowenBoost TargetOutperform$186.00 ➝ $210.00Low
11/18/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
11/13/2020MizuhoBoost TargetNeutral$150.00 ➝ $178.00Medium
11/5/2020Credit Suisse GroupBoost TargetNeutral$174.00 ➝ $178.00Medium
11/4/2020Morgan StanleyBoost TargetOverweight$204.00 ➝ $219.00High
11/4/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$202.00 ➝ $222.00High
11/2/2020BarclaysUpgradeEqual Weight ➝ Overweight$166.00 ➝ $166.00Medium
8/4/2020JPMorgan Chase & Co.Boost TargetPositive ➝ Overweight$187.00 ➝ $198.00Low
8/4/2020Credit Suisse GroupBoost TargetNeutral$160.00 ➝ $162.00Low
8/4/2020Morgan StanleyBoost TargetOverweight$194.00 ➝ $204.00Medium
8/4/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$169.00 ➝ $202.00Medium
7/8/2020GuggenheimBoost TargetBuy$168.00 ➝ $175.00Medium
6/15/2020Morgan StanleyBoost TargetOverweight$163.00 ➝ $194.00Medium
5/27/2020GuggenheimBoost TargetBuy$147.00 ➝ $168.00High
5/26/2020UBS GroupBoost TargetBuy$160.00 ➝ $165.00Low
5/22/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$184.00Low
5/22/2020Morgan StanleyBoost TargetOverweight$150.00 ➝ $163.00Low
5/21/2020CowenBoost TargetOutperform$174.00 ➝ $186.00Low
5/21/2020Deutsche Bank AktiengesellschaftLower TargetHold$173.00 ➝ $169.00Low
5/21/2020MizuhoBoost TargetNeutral$140.00 ➝ $147.00Low
5/20/2020CfraLower TargetBuy$179.00 ➝ $171.00Medium
5/15/2020UBS GroupUpgradeNeutral ➝ Buy$151.00 ➝ $160.00High
4/22/2020Credit Suisse GroupInitiated CoverageNeutral$146.00Low
4/2/2020Credit Suisse GroupLower TargetNeutral$155.00 ➝ $147.00High
3/31/2020BarclaysLower TargetEqual Weight$170.00 ➝ $163.00Medium
3/27/2020Morgan StanleyLower TargetOverweight$182.00 ➝ $150.00Low
3/18/2020Credit Suisse GroupReiterated RatingHold$145.00Medium
3/18/2020JPMorgan Chase & Co.Boost TargetOverweight$186.00 ➝ $187.00High
3/18/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$173.00 ➝ $174.00High
3/13/2020GuggenheimUpgradeNeutral ➝ BuyMedium
3/6/2020Morgan StanleyReiterated RatingBuy$182.00Medium
2/11/2020Morgan StanleyBoost TargetOverweight$168.00 ➝ $182.00Medium
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$164.00 ➝ $197.00Medium
2/5/2020Robert W. BairdBoost TargetNeutral$161.00 ➝ $164.00Medium
2/5/2020Deutsche Bank AktiengesellschaftBoost TargetHold$153.00 ➝ $173.00Medium
2/5/2020Morgan StanleyBoost TargetOverweight$162.00 ➝ $168.00Medium
1/19/2020BarclaysReiterated RatingHold$170.00Low
1/15/2020MizuhoBoost TargetNeutral$137.00 ➝ $140.00High
1/10/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$135.00 ➝ $162.00Medium
1/9/2020UBS GroupDowngradeSell$147.00High
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$155.00Medium
8/27/2019Morgan StanleyBoost TargetEqual Weight$130.00 ➝ $135.00High
8/5/2019Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
7/31/2019Bank of AmericaSet TargetBuy$160.00N/A
7/22/2019Credit Suisse GroupInitiated CoverageNeutral$143.00Low
7/22/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$152.00Low
7/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight$164.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 39 very positive mentions
  • 64 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
9/29/2023
  • 29 very positive mentions
  • 42 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
10/29/2023
  • 14 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2023
  • 25 very positive mentions
  • 35 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 42 very positive mentions
  • 37 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
1/27/2024
  • 37 very positive mentions
  • 42 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 41 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 40 very positive mentions
  • 36 positive mentions
  • 14 negative mentions
  • 6 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 40 very positive mentions
  • 36 positive mentions
  • 14 negative mentions
  • 6 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

McKesson logo
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Read More

Today's Range

Now: $539.94
Low: $534.72
High: $542.30

50 Day Range

MA: $527.50
Low: $506.74
High: $540.10

52 Week Range

Now: $539.94
Low: $352.34
High: $543.00

Volume

446,710 shs

Average Volume

686,906 shs

Market Capitalization

$70.95 billion

P/E Ratio

24.46

Dividend Yield

0.47%

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of McKesson?

The following Wall Street analysts have issued stock ratings on McKesson in the last twelve months: 58.com Inc., Argus, Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., Leerink Partnrs, Mizuho, Morgan Stanley, Robert W. Baird, StockNews.com, SVB Leerink LLC, TD Cowen, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for MCK.

What is the current price target for McKesson?

14 Wall Street analysts have set twelve-month price targets for McKesson in the last year. Their average twelve-month price target is $533.50, suggesting a possible downside of 1.2%. UBS Group AG has the highest price target set, predicting MCK will reach $620.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $475.00 for McKesson in the next year.
View the latest price targets for MCK.

What is the current consensus analyst rating for McKesson?

McKesson currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MCK.

What other companies compete with McKesson?

Other companies that are similar to McKesson include Cencora, Cardinal Health, Zoetis, Becton, Dickinson and Company and Gilead Sciences. Learn More about companies similar to McKesson.

How do I contact McKesson's investor relations team?

McKesson's physical mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company's listed phone number is (972) 446-4800 and its investor relations email address is [email protected]. The official website for McKesson is www.mckesson.com. Learn More about contacing McKesson investor relations.